PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...
The EXODUS system is an advanced exosome isolation technology, offering significant improvements in yield, purity, and ...
Paulick Report on MSN9mon
Study: Iron Inflammatory Markers May Indicate Severity Of ColicCanola and a team of researchers analyzed ferritin, which stores iron and increases during acute inflammation, and ...
The clinical utility of screening of biochemical parameters in elite athletes: analysis of 100 cases
Intervention: Initial and follow-up assessment of the following biochemical parameters in association with clinical assessment; serum iron, ferritin, transferrin, percent transferrin saturation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback